A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Inclusion Criteria: * BMI ≥ 18 and ≤ 23 kg/m2 * Able to provide written informed consent * Routine clinical laboratory tests either within normal limits or not clinically meaningful if outside of normal limits * AST, ALT, Tbili within normal limits at screening * Medical and psychiatric history and physical examination devoid of any significant findings that would interfere with participation or interpretation of results in this study * Agree to use a barrier method of birth control for 28 days following the last dose of study medication * Have maintained a stable weight for at least 6 months prior to Screening Exclusion Criteria: * Prior or current history of any psychiatric disorder, including eating disorders such as anorexia nervosa, bulimia nervosa, or binge-eating disorder * Positive urine drug screen for any drug of abuse (including amphetamines, cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) unless prescribed by a physician * Participation in a clinical investigation of any drug, biological or other investigational therapy within 30 days prior to dosing * Have a history of an allergic reaction to either mifepristone or risperidone * Any other clinically significant abnormality on screening laboratory tests * QTc Bazzett's ≥ 450 msec * History of or current major medical condition, which in the opinion of the Investigator would place the patient at undue risk. * Receiving any prescription or over-the-counter medications that could potentially affect appetite or weight * Any history of a movement disorder such as Tardive Dyskinesia, Parkinsonism * Any personal or family history of Neuroleptic Malignant Syndrome